91 related articles for article (PubMed ID: 23324231)
1. [Clinicopathologic significance of β-catenin protein and loss of heterozygosity on 10q in medulloblastoma].
Li JZ; Wang CH; Zhou FA; Miao N; Abulajang G; Zhang W
Zhonghua Bing Li Xue Za Zhi; 2012 Dec; 41(12):823-7. PubMed ID: 23324231
[TBL] [Abstract][Full Text] [Related]
2. [Clinical and pathologic analysis of astrocytic tumors with loss of heterozygosity on chromosome 10q].
Zhou FA; Li JZ; Ma YQ; Miao N; Liu X; Li XX; Zhang W
Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):618-21. PubMed ID: 23157831
[TBL] [Abstract][Full Text] [Related]
3. Adult and pediatric medulloblastomas are genetically distinct and require different algorithms for molecular risk stratification.
Korshunov A; Remke M; Werft W; Benner A; Ryzhova M; Witt H; Sturm D; Wittmann A; Schöttler A; Felsberg J; Reifenberger G; Rutkowski S; Scheurlen W; Kulozik AE; von Deimling A; Lichter P; Pfister SM
J Clin Oncol; 2010 Jun; 28(18):3054-60. PubMed ID: 20479417
[TBL] [Abstract][Full Text] [Related]
4. beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee.
Ellison DW; Onilude OE; Lindsey JC; Lusher ME; Weston CL; Taylor RE; Pearson AD; Clifford SC;
J Clin Oncol; 2005 Nov; 23(31):7951-7. PubMed ID: 16258095
[TBL] [Abstract][Full Text] [Related]
5. Correlation of loss of heterozygosity at chromosome 9q with histological subtype in medulloblastomas.
Schofield D; West DC; Anthony DC; Marshal R; Sklar J
Am J Pathol; 1995 Feb; 146(2):472-80. PubMed ID: 7856756
[TBL] [Abstract][Full Text] [Related]
6. Nuclear expression of β-catenin and stem cell markers as potential prognostic indicators in medulloblastoma.
Gowda KK; Gupta K; Kapoor R; Vasishta RK
Neurol India; 2012; 60(5):487-94. PubMed ID: 23135025
[TBL] [Abstract][Full Text] [Related]
7. CTNNB1, AXIN1 and APC expression analysis of different medulloblastoma variants.
Silva Rd; Marie SK; Uno M; Matushita H; Wakamatsu A; Rosemberg S; Oba-Shinjo SM
Clinics (Sao Paulo); 2013; 68(2):167-72. PubMed ID: 23525311
[TBL] [Abstract][Full Text] [Related]
8. Loss of heterozygosity on chromosome 10q associated with malignancy and prognosis in astrocytic tumors, and discovery of novel loss regions.
Daido S; Takao S; Tamiya T; Ono Y; Terada K; Ito S; Ouchida M; Date I; Ohmoto T; Shimizu K
Oncol Rep; 2004 Oct; 12(4):789-95. PubMed ID: 15375501
[TBL] [Abstract][Full Text] [Related]
9. Beta-catenin status in paediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics.
Fattet S; Haberler C; Legoix P; Varlet P; Lellouch-Tubiana A; Lair S; Manie E; Raquin MA; Bours D; Carpentier S; Barillot E; Grill J; Doz F; Puget S; Janoueix-Lerosey I; Delattre O
J Pathol; 2009 May; 218(1):86-94. PubMed ID: 19197950
[TBL] [Abstract][Full Text] [Related]
10. Correlation of chromosome 17p loss with clinical outcome in medulloblastoma.
Emadian SM; McDonald JD; Gerken SC; Fults D
Clin Cancer Res; 1996 Sep; 2(9):1559-64. PubMed ID: 9816333
[TBL] [Abstract][Full Text] [Related]
11. Characteristics of medulloblastoma in children under age of three years.
Ryzhova MV; Zheludkova OG; Kumirova ÉV; Shishkina LV; Panina TN; Gorelyshev SK; Khukhlaeva EA; Mazerkina NA; Matuev KB; Medvedeva OA; Tarasova EM; Kholodov BV; Kapitul'skaia OIu
Zh Vopr Neirokhir Im N N Burdenko; 2013; 77(1):3-10; discussion 11. PubMed ID: 23659115
[TBL] [Abstract][Full Text] [Related]
12. Histological variants of medulloblastoma are the most powerful clinical prognostic indicators.
Massimino M; Antonelli M; Gandola L; Miceli R; Pollo B; Biassoni V; Schiavello E; Buttarelli FR; Spreafico F; Collini P; Giangaspero F
Pediatr Blood Cancer; 2013 Feb; 60(2):210-6. PubMed ID: 22693015
[TBL] [Abstract][Full Text] [Related]
13. Analysis of loss of heterozygosity on chromosomes 10q, 11, and 16 in medulloblastomas.
Yin XL; Pang JC; Liu YH; Chong EY; Cheng Y; Poon WS; Ng HK
J Neurosurg; 2001 May; 94(5):799-805. PubMed ID: 11354413
[TBL] [Abstract][Full Text] [Related]
14. [Analysis of pathologic characteristics and prognosis in different subtypes of adult medulloblastoma].
Zhao F; Zhang J; Wang X; Wang Z; Wang Y; Qu P; Luo L; Liu P
Zhonghua Bing Li Xue Za Zhi; 2014 Mar; 43(3):169-72. PubMed ID: 24842015
[TBL] [Abstract][Full Text] [Related]
15. Clinical and molecular stratification of disease risk in medulloblastoma.
Gilbertson R; Wickramasinghe C; Hernan R; Balaji V; Hunt D; Jones-Wallace D; Crolla J; Perry R; Lunec J; Pearson A; Ellison D
Br J Cancer; 2001 Sep; 85(5):705-12. PubMed ID: 11531256
[TBL] [Abstract][Full Text] [Related]
16. C-MYC expression in medulloblastoma and its prognostic value.
Herms J; Neidt I; Lüscher B; Sommer A; Schürmann P; Schröder T; Bergmann M; Wilken B; Probst-Cousin S; Hernáiz-Driever P; Behnke J; Hanefeld F; Pietsch T; Kretzschmar HA
Int J Cancer; 2000 Sep; 89(5):395-402. PubMed ID: 11008200
[TBL] [Abstract][Full Text] [Related]
17. Correlation of gamma-catenin expression with good prognosis in medulloblastomas.
Misaki K; Marukawa K; Hayashi Y; Fukusato T; Minamoto T; Hasegawa M; Yamashita J; Fujisawa H
J Neurosurg; 2005 Mar; 102(2 Suppl):197-206. PubMed ID: 16156230
[TBL] [Abstract][Full Text] [Related]
18. The expression of FAT1 is associated with overall survival in children with medulloblastoma.
Yu J; Li H
Tumori; 2017 Jan; 103(1):44-52. PubMed ID: 27834469
[TBL] [Abstract][Full Text] [Related]
19. Medullomyoblastoma: a radiographic and clinicopathologic analysis of six cases and review of the literature.
Helton KJ; Fouladi M; Boop FA; Perry A; Dalton J; Kun L; Fuller C
Cancer; 2004 Sep; 101(6):1445-54. PubMed ID: 15368333
[TBL] [Abstract][Full Text] [Related]
20. Large cell/anaplastic medulloblastomas and medullomyoblastomas: clinicopathological and genetic features.
Leonard JR; Cai DX; Rivet DJ; Kaufman BA; Park TS; Levy BK; Perry A
J Neurosurg; 2001 Jul; 95(1):82-8. PubMed ID: 11453402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
